Flucloxacillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Flucloxacillin: From Staphylococcal Infections to Conjunctivitis
One-Sentence Summary
Flucloxacillin is a narrow-spectrum, penicillinase-resistant β-lactam antibiotic traditionally used against susceptible staphylococcal and streptococcal infections. The TxGNN model predicts it may be effective for Conjunctivitis, but this is currently supported only by 0 clinical trials and 2 indirect publications, none of which studied flucloxacillin for this indication directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded (data gap); pharmacologically, staphylococcal/streptococcal infections based on drug class |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 (mechanism-based, no direct clinical evidence) |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for flucloxacillin is not available from DrugBank (flagged as a High-severity data gap). Based on known pharmacological classification, flucloxacillin is a narrow-spectrum, penicillinase-resistant isoxazolyl penicillin with established antibacterial activity against Staphylococcus aureus and other Gram-positive organisms.
Bacterial conjunctivitis can be caused by S. aureus and related organisms, so there is a plausible general antibacterial-spectrum rationale for flucloxacillin’s activity in this setting. However, this is a class-level extrapolation rather than indication-specific pharmacological evidence — nothing in the evidence pack directly links flucloxacillin’s mechanism to ocular/conjunctival tissue penetration or efficacy.
Importantly, the two literature items identified both discuss conjunctivitis only as a secondary or prodromal clinical feature of unrelated conditions (staphylococcal scalded skin syndrome; atypical herpes simplex presentations) rather than as a treatment target for flucloxacillin itself. The TxGNN graph-based score is therefore likely capturing a co-occurrence signal (staphylococcal disease ↔ conjunctivitis) rather than direct treatment evidence, which is consistent with the model’s own L4/Hold classification for this candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12627992 | 2003 | Review | American Journal of Clinical Dermatology | Reviews staphylococcal scalded skin syndrome (SSSS); notes conjunctivitis as a prodromal symptom, not a flucloxacillin treatment study |
| 1286123 | 1992 | Review/Case report | International Journal of STD & AIDS | Reviews atypical presentations of herpes simplex virus infection; abstract unavailable, no direct relevance to flucloxacillin established |
Taiwan Market Information
Flucloxacillin currently has no marketing authorization records in Taiwan (0 registrations, status: Not marketed/Not Marketed).
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications and DDI database results were not retrievable at time of this report — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The conjunctivitis prediction rests on L4 (mechanism/graph-inference) evidence only, with no clinical trials and no literature directly evaluating flucloxacillin for this indication. The drug also has no current market presence in Taiwan and a blocking gap in TFDA safety data, which prevents any safety pre-assessment (S1 stage).
To proceed, the following is needed:
- TFDA product label (warnings/contraindications) — blocking gap, required before S1 safety review
- DrugBank mechanism of action detail — required for mechanistic-relevance analysis
- Indication-specific preclinical or clinical data on flucloxacillin in bacterial conjunctivitis
- Complete DDI database query (current query failed due to missing local DDInter data file)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.